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Background: Early detection of epithelial ovarian cancer (OC) is necessary to overcome the high mortality rate of
late stage diagnosis; and, examining the molecular changes that occur at early disease onset may provide new
strategies for OC detection. Since the deregulation of inflammatory mediators can contribute to OC development,
the purpose of this pilot study was to determine whether elevated urinary levels of Interleukin-1beta (IL-1 beta) are
associated with OC and associated clinical parameters.
Methods: Urinary and serum levels of IL-1 beta were analyzed by ELISA from a patient cohort consisting of healthy
women (N = 10), women with ovarian benign disease (N = 23), women with OC (N = 32), women with other benign
gynecological conditions (N = 22), and women with other gynecological cancers (N = 6).
Results: Average urinary IL-1 beta levels tended to be elevated in ovarian benign (1.26 pg/ml) and OC (1.57 pg/ml)
patient samples compared to healthy individuals (0.36 pg/ml). Among patients with benign disease, urinary IL-1β
levels were statistically higher in patients with benign inflammatory gynecologic disease compared to patients with
non-inflammatory benign disease. Interestingly, urinary IL-1 beta levels tended to be 3-6x greater in patients with
benign ovarian disease or OC as well as with a concomitant family history of ovarian and/or breast cancer compared to
similar patients without a family history of ovarian and/or breast cancer. Lastly, there was a pattern of increased urinary
IL-1 beta with increasing body mass index (BMI); patients with a normal BMI averaged urinary IL-1 beta levels of
0.92 pg/ml, overweight BMI averaged urinary IL-1 beta levels of 1.72 pg/ml, and obese BMI averaged urinary IL-1 beta
levels of 5.26 pg/ml.
Conclusions: This pilot study revealed that urinary levels of IL-1 beta are elevated in patients with epithelial OC
supporting the thought that inflammation might be associated with cancer progression. Consequently, further studies
of urinary IL-1 beta and the identification of an inflammatory profile specific to OC development may be beneficial to
reduce the mortality associated with this disease.
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Ovarian cancer (OC) is the fifth leading cause of cancer
death among women after lung, breast, colorectal, and
pancreatic cancer [1]. OC is highly treatable when diag-
nosed in the early stages; however, the majority of cases
are diagnosed in late stage and the 5-year survival is ap-
proximately 27% [1]. In order to detect early stages of
OC, there is a need for a better understanding of the* Correspondence: pkruk@health.usf.edu
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unless otherwise stated.etiology of this disease as well as improved screening op-
tions. Currently, there are three screening procedures in
use for OC detection: bimanual pelvic examination, serum
CA125, and transvaginal ultrasonography (TVS) [2]. Pelvic
examinations are not effective in distinguishing a prema-
lignant lesion from a normal ovary [3]. Serum CA125 is el-
evated in 47% of women with early stage OC and elevated
in 80-90% of advanced stage OCs [4]. However, CA125
can also be elevated in healthy women and in patients
with benign ovarian disease [5]; as well as, in other cancers
such as endometrial, pancreatic, lung, breast, colorectal,
and certain gastrointestinal tumors [6]. The pairing of
TVS with serum CA125 improves OC diagnosis; however,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Histologic diagnoses and clinical characteristics
of the study cohort
Age (mean ± SD) Age (range)
USF +MCC cohort
Normal (10) 49.3 ± 10.3 37-66
Benign (23) 52.68 ± 17.7 28-81
Serous cystadenoma (8)
Mucinous cystadenoma (3)










42.59 ± 9.5 30-62
Other gynecological cancers (6) 59.17 ± 8.2 20-77
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sary surgery [7]. Unfortunately, utilizing these methods ei-
ther alone or in combination does not produce the desired
results for early disease detection. Therefore, examining the
molecular changes that occur at early disease onset may
provide new approaches or biomarkers for OC detection.
Deregulation of inflammation due to overexpression of
proinflammatory proteins contributes to the malignant
phenotype by supporting cancer cell growth and tumor in-
vasion. Since the proinflammatory cytokine, interleukin-1β
(IL-1β), is constitutively expressed in OC [8] and elevated
in serum of OC patients [9], in this pilot study, we sought
to assess whether elevated urinary levels of IL-1β are associ-
ated with OC and related clinical parameters.
Methods
Patient cohort
With prior University of South Florida Institutional Review
Board committee approval for study # 4739, urine and
serum samples were collected from an initial cohort of
healthy controls (N = 7), women with ovarian benign disor-
ders (N = 12), and patients with epithelial OC (N = 20) at
the H. Lee Moffitt Cancer Center (MCC). The second urine
and serum cohort collected with University of South Flor-
ida Institutional Review Board committee approval for
study # Pro00003119 at the University of South Florida
(USF) consisted of healthy controls (N = 3), women with
ovarian benign disease (N = 11), women with epithelial OC
(N= 12), women with other benign gynecologic disease
(N = 22), and other gynecologic cancers (N = 6). The OC
category, diagnosed at time of initial cytoreductive surgery,
consisted of women diagnosed with OC and primary peri-
toneal cancer, which is often related to OC. The samples
collected from women with ovarian benign disease con-
sisted of a broad range of non-malignant gynecologic disor-
ders. Though these 93 samples comprise a small pilot study
(Table 1), they are representative of a typical clinical prac-
tice with regards to histological distribution. Table 1 shows
an age matched subset (N = 87) developed from the OC pa-
tients in the USF +MCC cohorts to produce an OC patient
group with an age range (26–75 years) within two standard
deviations of mean age to match healthy control (37–60
years) and ovarian benign disease (28–81) groups, respect-
ively. Where possible, H & E sections from paraffin blocks
were reviewed to confirm the histologic diagnosis according
to International Federation of Gynecology and Obstetrics
(FIGO) scores. H & E sections were also reviewed among
patients with benign disease to distinguish between pa-
tients with inflammatory disease (including endometri-
osis, pelvic inflammatory disease) and non-inflammatory
disease (including cystademona, leiomyoma, ovarian
cysts). Anonymized information regarding patient age,
body mass index (BMI), and tumor type were also ob-
tained as per availability.Sample preparation
Urine and serum samples were collected from patients,
anonymized to protect patient identity, and released
from the tissue banks for this research project. All sam-
ples were kept on ice following collection. MCC urine
samples were treated with a standard protease inhibitor
cocktail (80 ug/mL 4-(2 aminoethyl)-benzene sulfonyl fluor-
ide, 200 ug/mL ethylenediaminetetraacetic acid (EDTA),
0.2 ug/mL leupeptin, 0.2 ug/mL pepstatin, Sigma Scientific,
St. Louis, MI). All urine samples were centrifuged at
3000 × g. Urinary supernates and serum samples were then
aliquoted and stored at −20°C.
Enzyme-linked immunosorbant assay
To measure IL-1β levels in patients’ urine and serum, sam-
ples were assayed using the quantitative sandwich enzyme-
linked immunosorbant assay (ELISA; R&D Systems, Inc.,
Minneapolis, MN) according to the manufacturer’s instruc-
tions. Fluorescence was read on an ELx800 Absorbance
Microplate Reader (Biotek, Winooski, Vermont) using











































































































Figure 1 (See legend on next page.)
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Figure 1 Urinary and serum levels of IL-1β are elevated in 20–29 and 30–39 years age groups. ELISA was utilized to measure IL-1β
(mean pg/ml) in the urine and serum of study samples. (A) Urinary levels in all samples (N = 92). (B) Urinary levels in age matched subset
(N = 86). (C) Serum levels in available samples. Samples were examined in triplicate and the data expressed as mean IL-1β levels (pg/ml) per age
decade (mean value noted above bar depicting age decades with number of patients/decade category indicated in parenthesis) following
descriptive, parametric and Kruskal-Wallis analyses.
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expressed as the mean IL-1β concentration of triplicate
samples ± standard error (S.E.).
Statistical analysis
Samples for IL-1β ELISA were run in triplicate and the
data subjected to descriptive, parametric, Kruskal-Wallis,
Mann–Whitney U, Spearman correlation, and Wilcoxon
W analyses.
Results
Urinary levels of IL-1β generally decrease with increasing
patient age
Levels of urinary IL-1β were compared in 93 patients of
the entire cohort and 87 patients of the age matched
subset. Though this cohort comprises a small pilot
study, it is representative of our institutional clinical
practice in regard to OC histology and stage distribution
as well as in keeping with other comparable pilot stud-
ies. Average urinary IL-1β levels were compared to pa-
tient age and as divided by decade grouping. The highest
levels of urinary IL-1β were found in the 20–29 and 30–
39 age groups in both the entire cohort (Figure 1A) and
the age matched subset (Figure 1B), respectively, sug-
gesting an inverse relationship between increasing age
and urinary IL-1β levels. Additionally, levels of serum
IL-1β were compared in 19 patients of the entire cohort.
In agreement with comparisons between urinary IL-1β
levels and age, the highest average serum IL-1β level was
detected in the 20–29 age group (Figure 1C), further
suggesting a possible inverse correlation between age
and IL-1β levels. Despite the tendency for increased
urinary IL-1β levels in the 20–29 and 30–39 age groups,
no statistical differences were found.
Urinary IL-1β levels appear elevated in patients with
ovarian cancer
The levels of urinary IL-1β were generally negligible
(average 0.36 pg/ml) in healthy control samples of the
entire cohort and the age matched subset, respectively
(Figure 2A and B). However, urinary IL-1β levels from
women with benign ovarian disease were approximately
4-fold higher compared to healthy controls (average be-
nign 1.26 pg/ml) (Figure 2A and B). Urinary levels of IL-
1β from OC patients exhibited the highest average levels
of 1.57 pg/ml IL-1β in the entire cohort (Figure 2A) and
1.88 pg/ml IL-1β in the age matched subset (Figure 2B),respectively. Further, levels of urinary IL-1β in non-ovarian
benign gynecological disorders (average 1.56 pg/ml) and in
non-ovarian gynecological cancers (average 1.36 pg/ml)
were statistically increased compared to healthy controls
(p ≤0.005 and 0.05, respectively) (Figure 2A and B). Lastly,
when urinary IL-1β levels were compared among patients
with benign disease, but differentiated on the basis of noted
inflammatory involvement (including endometriosis, pelvic
inflammatory disease), average urinary IL-1β levels were
statistically increased in inflammatory benign disorders
(1.88 pg/ml) compared to non-inflammatory benign disor-
ders (0.82 pg/ml) (p =0.001) (Figure 2C).
When urinary IL-1β levels were compiled in the age
matched cohort with respect to diagnosis and age, the
average age in the healthy controls, benign ovarian disor-
ders, and OC patients was 49.3, 52.2, and 57.7 years, re-
spectively (Figure 3A). The average urinary levels of IL-1β
in these healthy controls, benign ovarian disorders, and
OC patients was 0.36 pg/ml, 1.30 pg/ml, and 1.88 pg/ml,
respectively (Figure 3A) supporting a trend for increased
urinary IL-1β levels with disease progression.
Levels of corresponding urine and serum IL-1β were
available from 19 patients. Compared to controls, paired
serum IL-1β showed a similar pattern of increased aver-
age IL-1β levels in the benign ovarian and OC group,
respectively, with the highest average levels in the OC
group (Figure 3B). Since there was a significant Spearman
correlation between serum and urinary IL-1β levels in
ovarian benign disorders (r = 0.949, N = 4, p = 0.051) and
in ovarian cancers (r = 0.724, N = 11, p = 0.012), and there
was a very limited number of available serum samples, all
remaining clinical comparisons were completed in urine
samples only.
Urinary IL-1β levels are increased in patients with a family
history of cancer
Using the age matched cohort subset, urinary IL-1β
levels were analyzed with respect to a family history of
cancer though the BRCA1 status of these patients could
not be confirmed. While the number of specimens was
small, in a patient with benign ovarian disease and no
known family history of cancer, urinary IL-1β levels
were 0.33 pg/ml; while average levels were 0.96 pg/ml in
five patients with benign ovarian disease and a family
history of cancer (Figure 4A). Though we could not
identify the lack of family history of cancer in most of
the OC patients, in those OC patients with confirmed
AC
B
Figure 2 (See legend on next page.)
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Figure 2 Urinary IL-1β levels are elevated in ovarian cancer patients. Urinary samples were analyzed in triplicate by ELISA and data
expressed as mean in pg/ml noted above bar depicting clinical diagnostic category following descriptive, Mann–Whitney U and Wilcoxon W
analyses. (A) Entire cohort of healthy controls, benign ovarian disorders, ovarian cancer patients, other gynecological benign disorders, and other
gynecological cancers; (B) age matched subset of healthy controls, benign ovarian disorders, ovarian cancer patients, other gynecological benign
disorders, and other gynecological cancers. (C) Non-inflammatory benign disorders and inflammatory benign disorders in all benign ovarian and
other benign gynecological disorders.
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6.33 pg/ml (Figure 4A), while the average urinary IL-1β
levels of the remaining OC patients was 1.16 pg/ml. How-
ever, when sample 3119–13 which was about 20-fold
higher than other samples in the OC group was excluded
from the analyses, the average urinary IL-1β levels de-
creased to 1.01 pg/ml (Figure 4A).
Thirteen patient samples of the age matched subset
were further narrowed to 8 patients with a first degree
family history of ovarian and/or breast cancer. In two
patients with benign ovarian disease and a family history
of ovarian and/or breast cancer, average urinary IL-1β
levels were three times higher (0.99 pg/ml) compared to
patients with benign ovarian disease, but without a fam-
ily history of ovarian and/or breast cancer (0.33 pg/ml).
Likewise, among three patients with OC and a family
history of ovarian and/or breast cancer, average urinary
IL-1β levels were elevated (6.33 pg/ml) compared to OC
patients without a family history of ovarian and/or
breast cancer (1.16 pg/ml) (Figure 4B).
Urinary IL-1β levels correlate with body mass index (BMI)
Urinary IL-1β levels were measured in 23 patient sam-
ples of the age matched subset and compared with their
BMI. The classifications of BMI in kg/m2 as underweight
(≤18.5), normal (18.5-24.99), overweight (25–29.99), and
obese (>30) were employed according to World Health
Organization standards [10]. Patients with a normal BMI
had the lowest average urinary IL-1β levels of 0.92 pg/ml
while overweight patients had average urinary IL-1β
levels of 1.72 pg/ml, about double that found in normal
BMI patients (Figure 5A). Obese patients had the high-
est average urinary IL-1β levels of 5.26 pg/ml; however,
when samples 3119–2 and 3119–13 were excluded since
IL-1β levels were at least 15-fold higher than other sam-
ples in the obese group, urinary IL-1β levels averaged
1.33 pg/ml, comparable to overweight patients though still
greater than patients with normal BMI (Figure 5A). While
a single patient classified as underweight had a urinary IL-
1β level of 2.20 pg/ml (Figure 5A), overall urinary IL-1β
levels appeared to increase with increasing BMI.
Further analyses of urinary IL-1β levels with BMI and
clinical diagnosis revealed that healthy control patients
had an average normal BMI of 22.12 and the lowest
average urinary IL-1β level of 0.67 pg/ml (Figure 5B).
Patients with benign ovarian disease fell within the obeseBMI classification (31.94) and demonstrated a 4-fold higher
average urinary IL-1β level of 2.66 pg/ml (Figure 5B) com-
pared to the healthy controls. OC patients had an average
overweight BMI of 29.13 and 4.7-fold higher average urin-
ary IL-1β level of 3.15 pg/ml (Figure 3.5B) compared to the
control group. While these comparisons failed to achieve
statistical significance, overall, our data suggest a trend of
increased urinary IL-1β levels with increasing BMI.
Discussion
While inflammation is an essential biological process for
normal development and tissue homeostasis, it is also
involved in a number of pathologic conditions including
tissue injury, chronic inflammation, immunological dis-
eases, and cancer [11]. Epidemiological studies have
shown a link between chronic inflammation and risk for
cancer as evidenced by prolonged infection with Helico-
bacter pylori and gastric cancer, inflammatory bowel dis-
ease and colon cancer, and prostatitis and prostate
cancer [12]. In the ovary, chronic inflammation resulting
from repeated ovulatory wounding and repair promotes
oxidative stress which enhances DNA replication errors
and ultimately, oncogenesis [13]. Inflammation is regu-
lated by several factors that can either promote or inhibit
inflammation and since epithelial OCs are highly inflam-
matory, this pilot study evaluated urinary levels of the pro-
inflammatory mediator, IL-1β against clinical parameters
in order to gain a better understanding of this disease.
This study was able to evaluate four clinical parameters in
relation to urinary IL-1β levels: (1) patient age, (2) diagno-
sis, (3) family history of cancer, and (4) BMI.
When we considered patient age at the time of sample
collection, the highest levels of urinary IL-1β levels were
found in the 20–29 and 30–39 years age groups followed
by declining IL-1β levels as age increased. In keeping
with our findings and according to the American Society
for Reproductive Medicine, a woman’s potential repro-
ductive capacity begins to gradually decline at approxi-
mately 32 years of age and more rapidly decreases after
37 years of age [14]. IL-1β has been suggested to play a
role in female reproduction; specifically in ovulation and
oocyte maturation, and inflammatory-linked mecha-
nisms, such as production and activation of proteolytic
enzymes, prostaglandin production, nitric oxide produc-
tion, cellular metabolism, and steroidogenesis [15,16].
Therefore, it seems likely that after 40 years of age, there
Figure 3 (See legend on next page.)
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Figure 3 Urinary and serum IL-1β levels are elevated in ovarian cancer patients. IL-1β levels were measured and compared by (A) average
age and average level urinary IL-1β (pg/ml) per diagnosis of healthy (normal) (N = 10), benign ovarian disorder (N = 25), and ovarian cancer
(N = 27) or measured from (B) paired urinary and serum samples from normal, ovarian benign, and ovarian cancer patients. Samples were
analyzed in triplicate by ELISA and data expressed as mean (pg/ml) following descriptive, Mann–Whitney U and Wilcoxon W analyses (A, B) ±
standard deviation of age in years (A).
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maturation and ovulation decrease in preparation for
menopause. In contrast, Vural, et al. found higher
plasma levels of IL-1β in postmenopausal (≥48.6 years)
women than in premenopausal (30.5 ± 2.5 years) women
with levels of IL-1β decreasing below the premenopausal
levels only after hormone replacement therapy [17].
Therefore, it is possible that the sharp decrease in urin-
ary IL-1β levels seen in our study in women >60 years
may be due, in part, to the usage of hormone replace-
ment therapy; however, this clinical information was not
available for confirmation.
Urinary IL-1β levels alone had limited success in dif-
ferentiating disease status. IL-1β is present in the serum
and ascites of OC patients [9] and has been shown to be
involved with cancer tumorigenesis, angiogenesis, and
metastasis [18]. The inability of urinary IL-1β to differ-
entiate between benign and malignancy may be con-
founded by the inflammatory nature of so many benign
and cancer conditions. That is, many benign ovarian
conditions develop in an inflammatory microenviron-
ment. For instance, endometrioma, a form of endometri-
osis in the ovary, is a highly inflammatory condition [19]
which would expectedly result in high levels of urinary
IL-1β [20]. Proinflammatory markers including serum
C-reactive protein, IL-6, and IL-8 have all been used in
clinical studies in an attempt to differentiate between nor-
mal, benign tumor, and OC [21-23]. Immunohistochemi-
cal analyses have shown differential expression of IL-18
and its receptors in benign ovarian tumors, borderline
ovarian tumors, and ovarian carcinomas [24]. Therefore,
developing and employing a panel of inflammatory media-
tors, including urinary IL-1β, may eventually benefit differ-
ential diagnostic and prognostic outcomes of OC.
Patient samples with confirmed family history of can-
cer were limited in this small pilot study. Nonetheless,
urinary IL-1β levels tended to be highest in patients with
benign ovarian disease and a (first degree) family history
of breast and/or ovarian cancer compared to patients
with benign ovarian disease, but without a family history
of breast and/or ovarian cancer. Likewise, elevated levels
of urinary IL-1β were found among OC patients with a
family history of breast and/or ovarian cancer compared
to OC patients from families without a family history of
disease. This supports the recent dualistic model that epi-
thelial OCs arise as either two types: Type 1 and Type 2
[25]. Type 1 tumors may arise in a step-wise progressionfrom a benign precursor lesion such as, the highly in-
flammatory condition, endometriosis. However, it is im-
portant to remember that not all individuals at risk for
OC develop the disease so that secondary events, per-
haps beyond a family history, may be necessary to pro-
mote disease.
Obesity as a risk factor of OC remains controversial.
Recently, a meta-analysis of 47 epidemiological studies
found increased OC risk with high BMI [26]. The
Ovarian Cancer Association Consortium investigated 15
case–control studies and found overweight and obese
women were associated with increased risk of OC [27].
The National Institutes of Health also found that BMI
was significantly associated with increased OC risk in
women who never used hormone therapy [28]. Canchola,
et al. found a positive association between OC risk and
adult weight gain, waist circumference, and waist-to-hip
ratio, but no association to overall obesity as classified by
BMI [29]. In agreement, Delort, et. al. also noted high
waist-to-hip ratio associated with increased risk of OC
though they found no association with BMI [30]. In
contrast, Schouten, et al. reported no overall association
between BMI and risk of OC; however, they did report a
positive association with high BMI and increased OC risk
among premenopausal women [31]. More recent pro-
spective studies reported no significant relationship be-
tween BMI and OC risk, irrespective of menopausal status
[32,33]. Likewise, evidence reported by McGee, et. al. does
not support a risk for OC with weight or weight gain
among BRCA1 or BRCA2 mutation carriers [34]. Interest-
ingly, Engleland et al. also reported that the risk for OC
was not associated with adult BMI, but suggested a pos-
sible increased risk in women who were obese in young
adulthood [35].
In this pilot study, one of the most apparent clinical
features related to elevated urinary IL-1β was BMI. We
found increased urinary IL-1β levels associated with
higher BMI. Overweight and obese patients were most
likely to be diagnosed with OC and ovarian benign dis-
orders, respectively, while concomitantly demonstrating
the highest average urinary IL-1β levels. In contrast,
healthy controls with normal BMI exhibited the lowest
average urinary IL-1β. Among our data was a single pa-
tient case classified as underweight, but with elevated
urinary IL-1β levels and a diagnosis of OC. It is tempting
to speculate that this individual may have had cachexia
at the time of sample collection where weight loss due
Figure 4 Urinary IL-1β levels increase with familial history of cancer. Urinary IL-1β was analyzed in triplicate by ELISA and data expressed as
mean (pg/ml) ± standard error in age matched subset cohort following descriptive, Mann–Whitney U and Wilcoxon W analyses. (A) Patients with
family history of any cancer. (B) Patients with family history of ovarian and/or breast cancer in first degree family members only.
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Figure 5 Urinary IL-1β levels are elevated in overweight and obese patients. (A) Urinary IL-1β levels in patient samples in relationship to
BMI: Underweight (N = 1), Normal (N = 11), Overweight (N = 2), Obese (N = 9). Urinary IL-1β was analyzed in triplicate by ELISA and data expressed
as mean (pg/ml) ± standard error in the age matched subset cohort. (B) Average urinary IL-1β levels and average BMI per diagnosis category:
Normal (N = 2), Ovarian Benign (N = 9), Ovarian Cancer (N = 11). Data expressed as mean (pg/ml) ± standard error of BMI and mean urinary IL-1β
in age matched subset cohort following descriptive, Mann–Whitney U and Wilcoxon W analyses.
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of the tumor [36] could manifest as low BMI com-
pounded with elevated urinary IL-1β as a result of ad-
vanced disease.
Obesity and elevated IL-1β levels in OC patients may
contribute to OC mortality. While some studies have
shown no association between BMI five to ten years
prior to OC diagnosis and OC mortality [37,38], they do
suggest that obesity is associated with poor outcome [39].
Consequently, obesity itself may not be the leading factor
for increased OC mortality, but may act as a comorbidity
factor. For instance, difficulty of proper chemotherapy
dosages for obese patients may contribute to poor disease
outcome. A study of dosing practices of clinicians found
that a significant proportion of OC patients with advanced
disease were overweight or obese, as seen in the current
study, and under-dosing in obese populations was com-
mon [40]. The variability in dosing when prescribing
chemotherapy is largely due to concern for potential over-
dosing and chemotherapy associated toxicities [41]. High
mobility group A2 (HMGA2) is a protein that can regulate
transcription by altering chromatin architecture and facili-
tate the assembly of multiprotein complexes of transcrip-
tional factors [42]. It is overexpressed in serous OC
tumors, but not in normal ovarian epithelial cells [43].
OCs with high expression of HMGA2 and high BMI nega-
tively affected overall survival [44].
Lastly, obesity may increase tumor aggressiveness. In-
creased metabolic activity and glucose concentrations
driven by the Warburg effect [45] are associated with
highly aggressive OC cell lines [46]. In cancer, the
Warburg effect is regarded as a characteristic meta-
bolic process that may contribute to cell survival in a
stressful environment, such as the stress of chronic in-
flammation [47]. The Warburg effect suggests that cancer
cells produce energy predominately by glycolysis and lactic
acid production over oxidative phosphorylation [45]. An
in vivo obese mouse model demonstrated increased tumor
size and tumors in these obese mice had a unique molecu-
lar makeup noted by upregulation of inflammation genes
[48]. Obesity in OC patients may further exacerbate dis-
ease by contributing to an inflammatory environment.
Obesity-related type 2 diabetes is associated with chronic
inflammation [49-51] and IL-1β levels have been shown to
be correlated with obesity and obesity related disorders.
Individuals with combined elevated plasma levels of IL-1β
and IL-6 are at increased risk for developing type 2diabetes [52], but even mild weight loss in obese patients
resulted in a 45% decrease in serum IL-1β levels over a
three-year study period [53]. Leptin, an adipocytokine in-
volved in the pathogenesis of insulin resistance necessary
for developing type 2 diabetes, induces β-cell apoptosis
and impaired β-cell function by promoting IL-1β produc-
tion in human pancreatic islets [54]. Expression of leptin
is also positively correlated with BMI [55]. In the current
study, obese patients tended to have the highest urinary
IL-1β levels and increased urinary IL-1β may be indicative
of advanced disease. Consequently, urinary IL-1β levels/
BMI may prove to be useful prognostic indicator of gyne-
cologic disease.
The greatest limitation of urinary IL-1β as a biomarker
for OC is kidney function. Inflammatory mediators, in-
cluding IL-1β, are typically found elevated in the urine
and serum of patients with impaired kidney function
[56-58]. Furthermore, elevated levels of IL-1β have been
reported in vaginal secretions associated with gyneco-
logic infections; however, Basso, et al. were unable to de-
tect IL-1β in patient urine or serum [59]. Interestingly,
while the pH of our urine samples were within neutral
range suggesting the absence of urinary tract infections
and normal renal function, two samples in our study,
3119–2 and 3119–13, displayed unusually elevated urin-
ary IL-1β levels. Unfortunately, clinical information per-
taining to kidney injury/dysfunction or gynecological
infection was unavailable as it may have contributed to
excessive urinary levels of IL-1β. Clearly, the potential
for confounding clinical parameters to influence the im-
pact of urinary IL-1β levels for gynecologic disease war-
rants further investigation.
The data in this study are derived from a small pilot
study, but is representative of our institutional clinical
practice in regard to OC histology and stage distribution
as well as published pilot studies examining IL-1β in urine,
serum, and plasma [17,56,58-61] and other clinically rele-
vant pilot studies [62-66]. A normal baseline value for
urinary IL-1β in women has not yet been established in
the literature [67]. Therefore, further study with increased
sample size may assist in the development of statistically
significant baseline and threshold values that could be
used to differentiate between healthy, benign disorders,
and OC, as well as other clinical parameters such as meta-
bolic disruption. Further, urinary levels of IL-1β levels/
BMI as a prognostic indicator of gynecologic disease could
impact clinical practice.
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Overall, our pilot study suggests that elevated urinary IL-1β
may be associated with cancer progression so that the iden-
tification of an inflammatory profile specific to epithelial
OC may benefit non-invasive diagnostic and prognostic ap-
plications as well as lead to the development of adjuvant
therapies utilizing target-specific anti-inflammatory treat-
ments to reduce the mortality associated with this disease.
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